Start-up of the Week: Saudi chef’s fusion cuisine aims to satisfy all cultures

The main encouragement to start his business came from his family, friends and followers on social media. (Supplied)
Updated 19 September 2018
0

Start-up of the Week: Saudi chef’s fusion cuisine aims to satisfy all cultures

RIYADH: Mansour Ismail, owner and head chef at Chef Culture, said what makes his establishment unique is that people feel as if they are eating at home.
Chef Culture, in the north of the eastern province of Alkhobar, specializes in traditional Gulf and international fusion cuisine. It was launched on May 25 and provides catering and takeaway services.
“I started my restaurant because I believe I have a unique touch which is going to spread across the world,” Mansour told Arab News.
The main encouragement to start his business came from his family, friends and followers on social media, he added. Chef Culture’s signature dish is tandoori lamb, a reflection of the fusion of Gulf and Indian cuisine. “What makes this dish unique is the balance between the two cultures in terms of spices and flavor. This has always been the best-selling dish on our menu,” said Mansour.
Another example of mixed flavors is the Japanese dish shrimp tempura, which is made with Halabi pistachio. Mansour added that a popular order with their catering services has always been the cherry kebab, in which Gulf and Armenian flavors are blended together. What gives this dish its distinctive flavor is that its cherry sauce is made from fresh produce.
“Our main concentration in Chef Culture is in mixing different influences of food from around the world,” said Mansour. He added that all the dishes were created from scratch and took him through trial phases of tasting the food before he was satisfied with the end result of his creations.
The goal at Chef Culture is to showcase Gulf cuisine with an inter-national twist by providing a blend of flavors and a taste that suits the palates of different cultures.
Mansour’s message to aspiring chefs is that the food industry is growing at a rapid pace and that there are big opportunities for talented people to thrive in the culinary world.
He started cooking 12 years ago as an amateur, then decided to develop his hobby by attending cooking courses in India. The chef also attended local and international live cooking shows. This gave Mansour the idea to mix Gulf cuisine with others from around the world, particularly from India, to create his fusion food menu.


Jazz Pharma’s sleep disorder treatment gets US FDA nod

Updated 21 March 2019
0

Jazz Pharma’s sleep disorder treatment gets US FDA nod

  • The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea
  • The patent of Jazz's narcolepsy drug, Xyrem, were declared invalid by a US appeals court in July
The US Food and Drug Administration approved Jazz Pharmaceuticals Plc’s treatment for patients with a form of sleep disorder, the company said on Wednesday.
The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).
Solriamfetol is expected to be commercially available in the United States following the final scheduling decision by the Drug Enforcement Administration (DEA), Jazz said in a statement.
The approval comes as Jazz is trying to reduce its reliance on its blockbuster narcolepsy drug, Xyrem, whose patents were declared invalid by a US appeals court in July.
Xyrem is an approved treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy. It brought in sales of $1.4 billion in 2018 and accounted for about 70 percent of company’s revenue.
“Jazz is trying to reduce its reliance on Xyrem, and solriamfetol will be one of the drugs it plans to launch to do that,” Mizuho Securities USA analyst Irina Koffler said ahead of the agency’s decision.
“Solriamfetol is expected to be an important driver of both diversification and growth,” RBC Capital Markets analyst Randall Stanicky said in a note ahead of the approval.
Solriamfetol is expected to bring in revenue of $314 million by 2024, Stanicky said.
Narcolepsy is a chronic sleep disorder with overwhelming daytime drowsiness and sudden attacks of sleep, while obstructive sleep apnea is a potentially serious sleep disorder that can cause breathing to repeatedly stop and start.
“Narcolepsy is very disabling to people as they often get diagnosed young and stop their education and drop out of high school or college,” Koffler said.
“Sleep apnea is a different problem in the sense that a lot of people don’t know they have it, have trouble breathing at night and they even fall asleep during the day.”